Patents Assigned to Recurium IP Holdings, LLC
-
Patent number: 11813259Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: March 28, 2022Date of Patent: November 14, 2023Assignee: RECURIUM IP HOLDINGS, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Patent number: 11813260Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: May 26, 2023Date of Patent: November 14, 2023Assignee: Recurium IP Holdings, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Patent number: 11724971Abstract: Processes of making [1.1.1]propellane utilize reaction conditions that include reacting 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane with an effective amount of solid magnesium.Type: GrantFiled: August 12, 2020Date of Patent: August 15, 2023Assignee: Recurium IP Holdings, LLCInventors: Aditya Krishnan Unni, Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker
-
Patent number: 11590126Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: January 8, 2019Date of Patent: February 28, 2023Assignee: Recurium IP Holdings, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Patent number: 11344546Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: January 8, 2019Date of Patent: May 31, 2022Assignee: Recurium IP Holding, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Patent number: 11339103Abstract: Processes for making bicyclic compounds and precursors thereof, and particularly for making [1.1.1]propellane and bicyclo[1.1.1]pentane and derivatives thereof, utilize continuous flow reaction methods and conditions. A continuous process for making [1.1.1]propellane can be conducted under reaction conditions that advantageously minimize clogging of a continuous flow reactor. A continuous flow process can be used to make precursors of [1.1.1]propellane.Type: GrantFiled: September 6, 2018Date of Patent: May 24, 2022Assignee: RECURIUM IP HOLDINGS, LLCInventors: Joseph Robert Pinchman, Kevin Duane Bunker, Matthew M. Bio, Christopher Breen, Andrew M. Clausen, Yuanqing Fang, Hui Li, Jillian W. Sheeran
-
Patent number: 11339162Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.Type: GrantFiled: December 20, 2021Date of Patent: May 24, 2022Assignee: Recurium IP Holdings, LLCInventors: Guobao Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sayee Gajanan Hegde
-
Patent number: 11318134Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.Type: GrantFiled: January 8, 2019Date of Patent: May 3, 2022Assignee: Recurium IP Holdings, LLCInventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
-
Patent number: 11278532Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).Type: GrantFiled: August 4, 2020Date of Patent: March 22, 2022Assignee: Recurium IP Holdings, LLCInventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Sayee Gajanan Hegde, Peter Qinhua Huang, Kevin Duane Bunker, Fernando Donate
-
Patent number: 11261192Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: GrantFiled: February 26, 2019Date of Patent: March 1, 2022Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
-
Patent number: 11242327Abstract: Disclosed herein are compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), and methods of using compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It) as an analgesic.Type: GrantFiled: May 11, 2018Date of Patent: February 8, 2022Assignee: Recurium IP Holdings, LLCInventors: Chad Daniel Hopkins, Joseph Robert Pinchman, Kevin Duane Bunker, Deborah Helen Slee, Brant Clayton Boren, Mehmet Kahraman
-
Publication number: 20210395230Abstract: Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.Type: ApplicationFiled: August 17, 2021Publication date: December 23, 2021Applicant: Recurium IP Holdings, LLCInventors: Kevin Duane Bunker, Peter Qinhua Huang, Sunny Abraham, Joseph Robert Pinchman, Chad Daniel Hopkins, Deborah Helen Slee
-
Patent number: 11124518Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: GrantFiled: July 31, 2018Date of Patent: September 21, 2021Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Brant Clayton Boren, Kevin Duane Bunker, Hui Liu, Sunil Paliwal
-
Patent number: 11098030Abstract: Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.Type: GrantFiled: December 4, 2019Date of Patent: August 24, 2021Assignee: Recurium IP Holdings, LLCInventors: Kevin Duane Bunker, Peter Qinhua Huang, Sunny Abraham, Joseph Robert Pinchman, Chad Daniel Hopkins, Deborah Helen Slee
-
Patent number: 11065234Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: GrantFiled: May 5, 2020Date of Patent: July 20, 2021Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Patent number: 11065233Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: GrantFiled: May 5, 2020Date of Patent: July 20, 2021Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Patent number: 10975035Abstract: Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.Type: GrantFiled: April 9, 2019Date of Patent: April 13, 2021Assignee: Recurium IP Holdings, LLCInventors: Kevin Duane Bunker, Chuangxing Guo, Mark Charles Grier, Chad Daniel Hopkins, Joseph Robert Pinchman, Deborah Helen Slee, Peter Qinhua Huang, Mehmet Kahraman
-
Patent number: 10959989Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.Type: GrantFiled: May 5, 2020Date of Patent: March 30, 2021Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
-
Patent number: 10934304Abstract: Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.Type: GrantFiled: October 3, 2017Date of Patent: March 2, 2021Assignee: Recurium IP Holdings, LLCInventors: Peter Qinhua Huang, Mehmet Kahraman, Kevin Duane Bunker
-
Patent number: 10793504Abstract: Methods of preparing substituted bicyclo[0.1.1.1]pentane compounds of Formula (I) comprise reacting a compound of Formula (A) with a compound of Formula (B) in the presence of a first transition metal catalyst selected from a palladium catalyst and a nickel catalyst, where the variables R1, R2, X1 and X2 are as described herein.Type: GrantFiled: August 22, 2017Date of Patent: October 6, 2020Assignee: Recurium IP Holdings, LLCInventors: Joseph Robert Pinchman, Chad Daniel Hopkins, Kevin Duane Bunker, Peter Qinhua Huang
